home *** CD-ROM | disk | FTP | other *** search
- BUSINESS, Page 57Business NotesPHARMACEUTICALSThe Miracle Is Missing
-
-
-
- Just three years ago, Interleukin-2 was hailed as a
- breakthrough treatment for kidney cancer. Cetus, the California
- biotechnology company that developed the drug, hoped it would
- become the firm's first real moneymaker. That hope was dashed
- last week when the Food and Drug Administration declined to
- give the drug approval for widespread use until more thorough
- research is conducted. While IL-2 shrinks tumors in some
- patients, researchers contend that the drug can also trigger
- cardiac arrest and other serious complications. Cetus last
- month suspended clinical trials of IL-2 as a treatment for high
- blood pressure when findings proved inconclusive. After
- investing more than $100 million to develop the drug, Cetus now
- faces a battle to prove its value. In the past three weeks, the
- firm's stock has plunged from 20 1/2 to 10 5/8.
-
-
-
-
-
-
-
-
-